Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases
  • 3 months ago
Dr. Howard Burman, Ph.D, CEO of Coya Therapeutics Inc., were guests on Benzinga’s All Access.

Coya is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. The company is currently developing multi-modality Treg therapies for neurodegenerative, autoimmune and metabolic diseases.

Coya has secured key financing that is funding its research and development to enhance the body’s T cells.